Guest Editor(s)
-
- Jörg Schlaak, MD
- Director, Department of Internal medicine, Evangelisches Klinikum Niederrhein GmbH, Duisburg, Germany.
Website | E-mail
Special Issue Introduction
Hepatocellular carcinoma (HCC) is still the most common primary liver malignancy. HCC incidence has doubled, and mortality rates have increased in recent decades despite efforts for prevention and screening as well as the development of new technologies for diagnosis and treatment. More recently, the coronavirus pandemic has attracted worldwide attention while, somehow, other clinical subjects appear to have been out of focus. Nevertheless, constant progress has been made in the field of HCC, which has prompted us to encourage the leading experts to sum up the state of the art in the management of this tumour in 2021 at the beginning of the post coronavirus era. The following topics are to be covered:
1.Prevention of HCC and surveillance of high risk patients
2.Histopathology – when and what
3.Molecular diagnostics
4.Radiological imaging
5.Evaluation of liver function before and during therapy
6.To resect or not to resect
7.Liver transplantation – still a good idea?
8.Interventional therapies
9.Radiotherapies
10.Old and new drugs for HCC
Participants
1. Ali Canbay Department of Medicine, Universitätsklinikum Knappschaftskrankenhaus Bochum, Ruhr-Universität Bochum, Bochum, Germany.
2. Andrea Tannapfel Institute for Pathology, Ruhr University Bochum, Bochum, Germany.
3. Guido Guenther Heinrich Gerken Department of Gastroenterology and Hepatology, University of Essen, Essen, Germany.
4. Martin Karl Walz Institute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
The list is arranged in no particular order and being updated.
Submission Deadline
15 Jul 2021
Hepatoma Research
hrjournal.net
